Efficacy of structurally diverse aldose reductase inhibitors on experimental periodontitis in rats

Journal of Periodontology

Volumn 82, Issue 6, 2011, Pages 926-933

  Kador, Peter F ^a,b   O'Meara, James D ^c   Blessing, Karen ^b   Marx, David B ^d   Reinhardt, Richard A ^e  

^a Therapeutic Vision Inc   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c CREIGHTON UNIVERSITY   (United States)

^d UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Enzyme inhibitors; Models, animal; Periodontitis

Indexed keywords

ALDEHYDE REDUCTASE; ANTIOXIDANT; ENZYME INHIBITOR; FLUORENE DERIVATIVE; HYDANTOIN DERIVATIVE; IMIRESTAT; LIPOPOLYSACCHARIDE; NAPHTHALENE DERIVATIVE; QUERCETIN; SORBITOL; TOLRESTAT;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; CITRIC ACID CYCLE; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GLYCOLYSIS; MALE; METABOLISM; PERIODONTITIS; RAT; SPRAGUE DAWLEY RAT;

ALDEHYDE REDUCTASE; ALVEOLAR BONE LOSS; ANIMALS; ANTIOXIDANTS; CITRIC ACID CYCLE; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; FLUORENES; GLYCOLYSIS; HYDANTOINS; LIPOPOLYSACCHARIDES; MALE; NAPHTHALENES; PERIODONTITIS; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; SORBITOL;

EID: 79958234707     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2010.100442     Document Type: Article

References (57)

1. Vernillo AT. Diabetes mellitus: Relevance to dental treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:263-270. (Pubitemid 33608843)
2. Jordan RC. Diagnosis of periodontal manifestations of systemic diseases. Periodontol 2000 2004;34:217-229. (Pubitemid 41794538)
3. Soskolne WA, Klinger A. The relationship between periodontal diseases and diabetes: An overview. Ann Periodontol 2001;6:91-98.
4. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005;366:1809-1820. (Pubitemid 41642647)
5. Saremi A, Nelson RG, Tulloch-Reid M, et al. Periodontal disease and mortality in type 2 diabetes. Diabetes Care 2005;28:27-32. (Pubitemid 40095778)
6. Geismar K, Stoltze K, Sigurd B, Gyntelberg F, Holmstrup P. Periodontal disease and coronary heart disease. J Periodontol 2006;77:1547-1554. (Pubitemid 44740765)
7. Mealey B. Diabetes and periodontal diseases. J Periodontol 1999;70:935-949.
8. Golub LM, Nicoll GA, Iacono VJ, Ramamurthy NS. In vivo crevicular leukocyte response to a chemotactic challenge: Inhibition by experimental diabetes. Infect Immun 1982;37:1013-1020. (Pubitemid 12056722)
9. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-217. (Pubitemid 30603166)
10. Nishimura F, Iwamoto Y, Mineshiba J, Shimizu A, Soga Y, Murayama Y. Periodontal disease and diabetes mellitus: The role of tumor necrosis factor-alpha in a 2-way relationship. J Periodontol 2003;74:97-102. (Pubitemid 36175740)
11. Salvi GE, Yalda B, Collins JG, et al. Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. J Periodontol 1997;68:127-135. (Pubitemid 127518254)
12. He H, Liu R, Desta T, Leone C, Gerstenfeld LC, Graves DT. Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinology 2004;145:447-452. (Pubitemid 38094541)
13. Karima M, Kantarci A, Ohira T, et al. Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: Association with periodontitis. J Leukoc Biol 2005;78:862-870. (Pubitemid 41384402)
14. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000;105:1117-1124. (Pubitemid 30217696)
15. Kador PF, Hamada T, Reinhardt RA, Blessing K. Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats. Postgrad Med 2010;122:138-144.
16. Oates PJ. Aldose reductase inhibitors and diabetic kidney disease. Curr Opin Investig Drugs 2010;11:402-417.
17. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008;9:14-36. (Pubitemid 351201678)
18. Ramasamy R, Goldberg IJ. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res 2010;106:1449-1458.
19. Kador PF. Ocular pathology of diabetes mellitus. In: Tasman W, Jaeger EA, eds. Duane's Foundations of Clinical Ophthalmology, vol. 3. Philadelphia: Lippincott Williams & Wilkins; 2008:84.
20. Ramana KV, Friedrich B, Bhatnagar A, Srivastava SK. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells. FASEB J 2003;17:315-317.
21. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2002;277:32063-32070. (Pubitemid 34969017)
22. Chandra D, Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Role of aldose reductase in TNF-alpha-induced apoptosis of vascular endothelial cells. Chem Biol Interact 2003;143-144:605-612. (Pubitemid 36253606)
23. Ramana KV, Srivastava SK. Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine 2006;36:115-122. (Pubitemid 46290698)
24. Pladzyk A, Reddy AB, Yadav UC, Tammali R, Ramana KV, Srivastava SK. Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells. Invest Ophthalmol Vis Sci 2006;47:5395-5403. (Pubitemid 46723790)
25. Galvez AS, Ulloa JA, Chiong M, et al. Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: differential effects of sorbitol and mannitol. J Biol Chem 2003;278:38484-38494. (Pubitemid 37221743)
26. Tebbs SE, Gonzalez AM, Wilson RM. The role of aldose reductase inhibition in diabetic neutrophil phagocytosis and killing. Clin Exp Immunol 1991;84:482-487.
27. Boland OM, Blackwell CC, Clarke BF, Ewing DJ. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Diabetes 1993;42:336-340. (Pubitemid 23045039)
28. Kawamura T, Suzuki K, Matsumae H, Sano T, Sakamoto N, Hotta N. Effects of glucose and SNK-860, an aldose reductase inhibitor, on the polyol pathway and chemiluminescence response of human neutrophils in vitro. Diabet Med 1995;12:392-396.
29. Ihm SH, Yoo HJ, Park SW, Park CJ. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients. Metabolism 1997;46:634-638. (Pubitemid 27247296)
30. De Toni S, Piva E, Lapolla A, Fontana G, Fedele D, Plebani M. Respiratory burst of neutrophils in diabetic patients with periodontal disease. Ann N Y Acad Sci 1997;832:363-367. (Pubitemid 28045331)
31. Sato N, Kashima K, Uehara Y, Ohtani K, Shimizu H, Mori M. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes Care 1997;20:995-998. (Pubitemid 27224952)
32. Kashima K, Sato N, Sato K, Shimizu H, Mori M. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats. Endocrinology 1998;139:3404-3408. (Pubitemid 28512295)
33. Mazade MA, Edwards MS. Impairment of type III group B streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001;73:259-267. (Pubitemid 32709616)
34. Okayama N, Omi H, Okouchi M, et al. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: Neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. J Diabetes Complications 2002;16:321-326.
35. Cruz JW, Soto-Suazo MW, Hohman TC, Akamine EH, Zorn TT, Fortes ZB. Minalrestat and leukocyte migration in diabetes mellitus. Diabetes Metab Res Rev 2003;19:223-231. (Pubitemid 36675963)
36. Cruz JW, Oliveira MA, Hohman TC, Fortes ZB. Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2000;391:163-174. (Pubitemid 30138093)
37. Fukase S, Sato S, Mori K, Secchi EF, Kador PF. Polyol pathway and NADPH-dependent reductases in dog leukocytes. J Diabetes Complications 1996;10:304-313. (Pubitemid 27047306)
38. Hasegawa G, Obayashi H, Kitamura A, et al. Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy. Diabetes Res Clin Pract 1999;45:9-14. (Pubitemid 29356119)
39. Inaba M, Terada M, Nishizawa Y, et al. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: Possible involvement of the polyol pathway in bone metabolism. Metabolism 1999;48:904-909. (Pubitemid 29310048)
40. Kador PF, Inoue J, Secchi EF, et al. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Exp Eye Res 1998;67:203-208. (Pubitemid 28428268)
41. Kador PF, Inoue J, Blessing K. Anticataract activity of analogs of a sorbitol dehydrogenase inhibitor. J Ocul Pharmacol Ther 2004;20:333-344. (Pubitemid 39108898)
42. Varma SD, Mizuno A, Kinoshita JH. Diabetic cataracts and flavonoids. Science 1977;195:205-206. (Pubitemid 8039573)
43. Simard-Duquesne N, Greselin E, Gonzalez R, Dvornik D. Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat. Proc Soc Exp Biol Med 1985;178:599-605. (Pubitemid 15029471)
44. Kador PF, Lee JW, Fujisawa S, Blessing K, Lou MF. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. J Ocul Pharmacol Ther 2000;16:149-160. (Pubitemid 30235973)
45. Lee JY, Kim MJ, Moon CK, Chung JH. Degradation products of streptozotocin do not induce hyperglycemia in rats. Biochem Pharmacol 1993;46:2111-2113.
46. Ramamurthy NS, Xu JW, Bird J, et al. Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease. J Periodontal Res 2002;37:1-7.
47. Iwata T, Sato S, Jimenez J, et al. Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J Biol Chem 1999;274:7993-8001.
48. Wilson RM, Tomlinson DR, Reeves WG. Neutrophil sorbitol production impairs oxidative killing in diabetes. Diabet Med 1987;4:37-40. (Pubitemid 17226929)
49. Kador PF, Kinoshita JH, Brittain DR, Mirrlees DJ, Sennitt CM, Stribling D. Purified rat lens aldose reductase. Polyol production in vitro and its inhibition by aldose reductase inhibitors. Biochem J 1986;240:233-237. (Pubitemid 17191729)
50. Hamada Y, Araki N, Horiuchi S, Hotta N. Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant 1996;11(Suppl. 5):95-98. (Pubitemid 27062921)
51. Chiou SH, Chylack LT Jr., Bunn HF, Kinoshita JH. Role of nonenzymatic glycosylation in experimental cataract formation. Biochem Biophys Res Commun 1980;95:894-901. (Pubitemid 11242705)
52. Obrosova IG. How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 2002;50:3-35.
53. Inaba M. Effect of aldose reductase on the abnormality of calcium metabolism in diabetic patients. Clin Calcium 2006;16:1360-1365.
54. Liu R, Bal HS, Desta T, et al. Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res 2006;85:510-514. (Pubitemid 43945487)
55. Kador PF, Kinoshita JH, Sharpless NE. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem 1985;28:841-849. (Pubitemid 15012489)
56. Stewart LK, Soileau JL, Ribnicky D, et al. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism 2008;57(Suppl. 7):S39-S46. (Pubitemid 351814697)
57. Paliwal S, Sundaram J, Mitragotri S. Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br J Cancer 2005;92:499-502. (Pubitemid 40395530)